XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.2

Segments (Tables)

12 Months Ended

Mar. 31, 2024

Segments [Abstract]

Schedule of Segment of the Continuing Operations

The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2024:

		Retail drugstores				Online Pharmacy				Drug wholesale				Total
Revenue		$	75,678,470			$	31,857,883			$	47,004,724			$	154,541,077
Cost of goods			53,056,339				28,249,883				42,126,307				123,432,529
Gross profit		$	22,622,131			$	3,608,000			$	4,878,417			$	31,108,548
Selling expenses			21,680,509				4,770,855				934,223				27,385,587
General and administrative expenses			5,195,153				466,151				1,596,220				7,257,524
Loss from operations		$	(4,253,531	)		$	(1,629,006	)		$	2,347,974			$	(3,534,563	)
Depreciation and amortization		$	754,448			$	-			$	36,001			$	790,449
Total capital expenditures		$	855,497			$	-			$	1,168			$	856,665

The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2023:

		Retail drugstores				Online Pharmacy				Drug wholesale				Total
Revenue		$	83,351,768			$	32,385,089			$	33,075,119			$	148,811,976
Cost of goods			56,551,607				28,506,228				29,473,677				114,531,512
Gross profit		$	26,800,161			$	3,878,861			$	3,601,442			$	34,280,464
Selling expenses			23,644,339				4,266,799				1,266,025				29,177,163
General and administrative expenses			13,803,165				439,667				1,425,852				15,668,684
Stock based compensation			10,360,000				-				-				10,360,000
Loss from operations		$	(21,007,343	)		$	(827,605	)		$	909,565			$	(20,925,383	)
Depreciation and amortization		$	686,777			$	-			$	31,225			$	718,002
Total capital expenditures		$	303,312			$	-			$	704			$	304,016

The following table presents summarized information by segment of the continuing operations for the year ended March 31, 2022:

		Retail drugstores				Online Pharmacy				Drug wholesale				Total
Revenue		$	84,228,492			$	30,219,364			$	49,944,699			$	164,392,555
Cost of goods			57,290,850				26,621,314				43,961,351				127,873,515
Gross profit		$	26,937,642			$	3,598,050			$	5,983,348			$	36,519,040
Selling expenses			25,186,258				3,972,465				1,718,236				30,876,959
General and administrative expenses			6,766,022				285,062				1,136,092				8,187,176
Impairment of long-lived assets			148,795				-				-				148,795
Loss from operations		$	(5,163,433	)		$	(659,477	)		$	3,129,020			$	(2,693,890	)
Depreciation and amortization		$	1,234,419			$	-			$	22,072			$	1,256,491
Total capital expenditures		$	296,562			$	-			$	2,911			$	299,473

Schedule of net revenue from external customers through its retail drugstores by main products

In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company’s net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and 2022 were as follows:

		For the years ended
		March 31,
		2024				2023				2022
Prescription drugs		$	25,269,177			$	27,212,994			$	28,503,283
OTC drugs			31,542,597				32,358,339				35,658,864
Nutritional supplements			9,890,985				8,737,519				9,664,071
TCM			3,405,979				9,719,653				5,353,900
Sundry products			1,129,647				1,082,168				1,544,639
Medical devices			4,440,085				4,241,095				3,503,735
Total		$	75,678,470			$	83,351,768			$	84,228,492

The Company’s net revenue from external customers through online pharmacy by main product category is as follows:

		For the years ended
		March 31,
		2024				2023				2022
Prescription drugs		$	9,151,412			$	10,606,244			$	10,331,652
OTC drugs			12,969,313				13,870,953				11,473,177
Nutritional supplements			4,284,556				2,740,253				2,014,011
TCM			571,769				434,920				315,231
Sundry products			1,448,537				1,129,701				2,271,009
Medical devices			3,432,296				3,603,018				3,814,284
Total		$	31,857,883			$	32,385,089			$	30,219,364

The Company’s net revenue from external customers through wholesale by main product category is as follows:

		For the years ended
		March 31,
		2024				2023				2022
Prescription drugs		$	30,784,949			$	21,617,636			$	41,116,991
OTC drugs			11,323,730				10,289,987				7,903,824
Nutritional supplements			741,883				310,909				424,210
TCM			388,396				458,502				241,828
Sundry products			692,101				64,422				93,338
Medical devices			3,073,665				333,663				164,508
Total		$	47,004,724			$	33,075,119			$	49,944,699

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration